Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 1,600 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $44.49, for a total value of $71,184.00. Following the completion of the transaction, the director owned 3,596,886 shares in the company, valued at approximately $160,025,458.14. The trade was a 0.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Orbimed Advisors Llc also recently made the following trade(s):

• On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.60, for a total value of $530,294.00.
• On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.54, for a total value of $4,212,726.82.

Sionna Therapeutics Stock Performance

Shares of SION traded down $0.49 during mid-day trading on Thursday, reaching $43.79. The company had a trading volume of 179,798 shares, compared to its average volume of 219,243. The company’s 50 day simple moving average is $34.04 and its 200 day simple moving average is $23.96. The company has a market capitalization of $1.95 billion and a price-to-earnings ratio of -8.99. Sionna Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Raymond James Financial restated a “strong-buy” rating on shares of Sionna Therapeutics in a research report on Wednesday, November 5th. Royal Bank Of Canada initiated coverage on Sionna Therapeutics in a report on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 price target for the company. Wall Street Zen downgraded Sionna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Tuesday. Finally, Jones Trading assumed coverage on shares of Sionna Therapeutics in a research report on Monday, September 8th. They set a “buy” rating and a $46.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its holdings in Sionna Therapeutics by 8.8% during the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after acquiring an additional 529 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Sionna Therapeutics by 35.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Sionna Therapeutics during the 3rd quarter worth $30,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Sionna Therapeutics in the 2nd quarter worth about $45,000. Finally, The Manufacturers Life Insurance Company grew its position in Sionna Therapeutics by 13.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,038 shares of the company’s stock valued at $660,000 after buying an additional 4,489 shares during the period.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.